MyFinsight
Home
Blog
About
Contact
Download
Download image
Marketable securities
$576,603K
(-35.50%↓ Y/Y)
Cash and cash
equivalents
$482,488K
(121.96%↑ Y/Y)
Trade receivables,
net
$286,916K
(8.09%↑ Y/Y)
Prepaid expenses and
other current assets
$75,596K
(10.39%↑ Y/Y)
Inventory
$21,686K
(-3.14%↓ Y/Y)
Total current assets
$1,443,289K
(-1.66%↓ Y/Y)
Non-current marketable
securities
$603,603K
(-5.29%↓ Y/Y)
Right-of-use assets and other
non-current assets
$342,305K
(42.79%↑ Y/Y)
Deferred tax assets, net
$292,582K
(-30.34%↓ Y/Y)
Property and equipment,
net
$98,960K
(-17.11%↓ Y/Y)
Goodwill
$63,684K
(0.00%↑ Y/Y)
Total assets
$2,844,423K
(-3.50%↓ Y/Y)
Total liabilities and
stockholders equity
$2,844,423K
(-3.50%↓ Y/Y)
Total stockholders
equity
$2,161,319K
(-3.69%↓ Y/Y)
Total liabilities
$683,104K
(-2.90%↓ Y/Y)
Accumulated deficit
-$76,830K
(22.12%↑ Y/Y)
Additional
paid-in-capital
$2,234,411K
(-4.67%↓ Y/Y)
Total current
liabilities
$405,644K
(0.46%↑ Y/Y)
Non-current operating lease
liabilities
$173,038K
(-9.32%↓ Y/Y)
Other non-current
liabilities
$104,422K
(-4.11%↓ Y/Y)
Accumulated other
comprehensive income (loss)
$3,476K
(358.05%↑ Y/Y)
Common stock, 0.001 par
value 400,000 shares...
$262K
(-7.09%↓ Y/Y)
Other current
liabilities
$125,382K
(31.96%↑ Y/Y)
Accrued compensation
and benefits
$102,218K
(-6.93%↓ Y/Y)
Accrued clinical trial
liabilities
$65,742K
(13.40%↑ Y/Y)
Rebates and fees due to
customers
$59,896K
(-3.98%↓ Y/Y)
Accounts payable
$29,623K
(-22.43%↓ Y/Y)
Accrued collaboration
liabilities
$22,783K
(-43.58%↓ Y/Y)
Back
Back
Balance Sheet
source: myfinsight.com
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)
Exelixis-Logo-2023-svg
EXELIXIS, INC. (EXEL)